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Background: Ciproﬂoxacin is a commonly used antibiotic for urinary tract infection that interacts with
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terase inhibitors (PDEis), on the other hand, are commonly used drugs for the management of erectile
dysfunction. The group includes agents such as sildenaﬁl, vardenaﬁl, and tadalaﬁl.
Objectives: We investigated whether PDEi could interfere with the antibacterial activity of ciproﬂoxacin.
Methods: PDEis were tested in several reference bacteria, including Escherichia coli, Staphylococcus
aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Acinetobacter baumannii, Proteus mir-
abilis, and Klebsiella pneumoniae utilizing a standard disc diffusion method and measuring both zones of
inhibition and MIC.
Results: Results from both assays indicated that ciproﬂoxacin demonstrates potent activity against the
tested reference bacteria. Additionally, when bacteria were treated with a combination of ciproﬂoxacin
and sildenaﬁl, tadalaﬁl, or vardenaﬁl, the zones of the combination inhibition were signiﬁcantly reduced,
whereas the MIC values were signiﬁcantly greater than those of ciproﬂoxacin alone for all tested bacterial
strains. In an attempt to examine the mechanism by which PDEis interfere with the action of
ciproﬂoxacin, we utilized the in vitro E coli DNA gyrase cleavage assay. The results showed that PDEi
drugs had no effect on ciproﬂoxacin’s inhibition of E coli gyrase activity.
Conclusions: Pretreatment of various reference bacterial cells with PDEis largely inhibited the anti-
bacterial activity of ciproﬂoxacin.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Phosphodiesterase inhibitors (PDEis) are a widely used group of
oral therapy for erectile dysfunction. This group is selective for
cyclic guanosine monophosphate-speciﬁc phosphodiesterase
(PDE) type 5 present in corpora cavernosa.1 The group has 3 major
members: sildenaﬁl, vardenaﬁl, and tadalaﬁl.2 These agents differ
in their degree of selectivity in inhibiting PDE isoenzymes, in their
pharmacokinetic proﬁles, in their drug-food interactions, and in
their adverse effects.1,3 These agents have been shown to possess
antioxidative or oxidative stress-protective properties.4–5Inc. This is an open access article u
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asadeh).Ciproﬂoxacin is a ﬂuoroquinolone antibiotic that possesses
strong activity against gram-negative bacteria. Ciproﬂoxacin is
commonly used for the treatment of a number of infections such
as acute uncomplicated cystitis, urinary tract infections, acute
sinusitis, and chronic bacterial prostatitis.6 The mechanism of
antibacterial action of quinolone, including ciproﬂoxacin, involves
interfering with replication and transcription of DNA via inhibiting
bacterial DNA gyrase/topoisomerase II and DNA topoisomerase IV,
and further preventing DNA of bacteria from unwinding and
duplicating.7 Thus, complexes of quinolone-enzyme-DNA are
formed, leading to the production of cellular poisons and cell
death.8
Microbiologic studies of various bacteria ascertain the presence
of the guanosine monophosphate-PDE system in bacteria,9 which
could represent a possible pharmacologic target for sildenaﬁl and
similar agents in bacteria.10 Moreover, a previous study11 showed
that coadministration of ciproﬂoxacin and clarithromycinnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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This could point to a possible interaction with antibiotic agents
that are commonly administrated concomitantly with these
agents. We evaluated, for the ﬁrst time, the possible interaction
among members of the PDEi group and ciproﬂoxacin. The results
of our study could be of clinical signiﬁcance due to the common
use of PDEis, especially, sildenaﬁl, when antibiotics are used for
treatment of urinary tract infection.Materials and Methods
Chemicals
Ciproﬂoxacin used in this study was donated by Al-Hikma
Pharmaceuticals (Amman, Jordan). Sildenaﬁl was obtained from
Sigma-Aldrich Corporation (St Louis, Missouri). Vardenaﬁl and
tadalaﬁl were obtained from Orchid Chemical Supplies Ltd (Hang-
zhou, China). All drugs were used as raw material.Microbial culture and growth conditions
Antibacterial activity of ciproﬂoxacin and/or PDEi combinations
were evaluated against different reference bacteria, including
Escherichia coli ATTC 35218, Staphylococcus aureus ATTC29213,
Pseudomonas aeruginosa ATTC 9027, Staphylococcus epidermidis
ATTC 12228, Acinetobacter baumannii ATTC 17978, Proteus mirabilis
ATTC 12459, and Klebsiella pneumoniae ATTC 13883. The organisms
were stored at –701C in trypticase-soy broth and 20% glycerol (BBL
Microbiology Systems, Cockeysville, Maryland). When ready for
batch susceptibility testing, samples were thawed. MICs were
determined in accordance with the Clinical and Laboratory Stand-
ards Institute.12Table I
Comparison among the zones of inhibition (mm) of ciproﬂoxacin alone and
ciproﬂoxacin in the presence of sildenaﬁl, tadalaﬁl, or vardenaﬁl against standard
bacterial strains
Standard
bacterial
strains
Zones of inhibition (mm)*
Ciproﬂoxacin
Ciproﬂoxacin
þ sildenaﬁl
Ciproﬂoxacin
þ tadalaﬁl
Ciproﬂoxacin
þ vardenaﬁl
Escherichia coli 26.7 (0.6) 11.3 (1.5) 11.0 (1.0) 11. 7 (0.6)Antimicrobial susceptibility test
Antibiotic solutions were prepared on the day of use according
to the manufacturer’s recommendations. A wide range of cipro-
ﬂoxacin concentrations were tested against different organisms.
Serial 2-fold dilutions were added to molten BBL Muller-Hinton
Gold II agar (BBL Microbiology Systems). After slight cooling and
drying of the plates, a steers replicator was used to place aliquots
containing approximately 5  104 CFU per drop for 4 test strains.
The plates were incubated at 371C and read 24 hours later. In
experiments where 0.1 mg/mL ciproﬂoxacin was combined with
PDEi, PDEis were added to the media at a ﬁnal concentration of
100 mM. Results (ie, the mean of 3 independent experiments) were
recorded by measuring the zones of growth inhibition surrounding
the antibiotic-containing discs. The breakpoints indicated in the
tables of the Clinical and Laboratory Standards Institute guide-
lines12 were used to determine susceptibility and resistance.Staphylococcus
aureus
21 (1.0) 9. 7 (1.2) 9. 7 (0.6) 9.3 (1.5)
Pseudomonas
aeruginosa
23.3 (0.6) 11 (1.0) 10. 7 (0.6) 7.0 (2.0)
Staphylococcus
epidermidis
21. 7 (0.6) 10.3 (1.2) 10.3 (0.6) 11.3 (0.6)
Acinetobacter
baumannii
17. 7 (0.6) 8.3 (0.6) 7. 7 (0.6) 8.3 (0.6)
Proteus
mirabilis
18. 7 (0.6) 8. 7 (0.6) 8. 7 (0.6) 7. 7 (0.6)
Klebsiella
pneumoniae
12.0 (1.0) 4. 7 (0.6) 6. 7 (0.6) 5. 7 (0.6)
n The zones of inhibition values for ciproﬂoxacin alone were signiﬁcantly (P o
0.05) lower than those of combination of ciproﬂoxacin with sildenaﬁl, tadalaﬁl, or
vardenaﬁl for all tested bacterial strains. Results are presented as mean (SD) of
3 independent experiments.Determination of MIC
The MICs were determined by serial dilution method as
described previously.13 Brieﬂy, drugs were serially diluted and
added to 96-well plates that were prepared by
dispensing into each well 100 mL of an appropriate medium
(BBL Muller-Hinton Gold II agar; BBL Microbiology Systems) and
20 mL inoculum (containing about 5  104 CFU). After an 18-hour
incubation period at 371C, plates were read. MIC is deﬁned as the
lowest concentration at which no growth, a faint haze, or fewer
than 3 discrete colonies was detected. Plates were read in
duplicate and the highest MIC value was recorded.E coli DNA gyrase cleavage assay
The effect of PDEis on antigyrase activity of ciproﬂoxacin was
examined using the E coli DNA gyrase cleavage assay as described
by the manufacturer (Inspirals, Norwich, United Kingdom).
In brief, DNA gyrase was incubated with 0.5 mg supercoiled
pBR322 in a reaction volume at 371C for 1 hour in the presence
of 0.1 mg/mL ciproﬂoxacin and/or different PDEis (100 mM). SDS
and proteinase K (0.2% and 0.1 mg/mL ﬁnal concentrations,
respectively) were added before a further incubation at 371C for
30 minutes. About 10 mL reaction mixture was electrophoresized
using 1% agarose and bands were visualized using ethidium
bromide.Statistical analysis
Analysis was performed using GraphPad Prism software (ver-
sion 4.0, GraphPad Software, La Jolla, California). One-way ANOVA
followed by Tukey’s posttest were used to determine if there was
any statistically signiﬁcant difference. P values o 0.05 were
considered signiﬁcant.Results
We investigated the possible attenuating effect of a PDEi on the
antibacterial activity of ciproﬂoxacin against various species of
reference bacteria, namely, E coli, Staphylococcus aureus, Pseudo-
monas aeruginosa, Staphylococcus epidermidis, A baumannii, Proteus
mirabilis, and K pneumoniae. Inhibition zones suggested in the
Clinical and Laboratory Standards Institute guidelines were con-
sidered representative of bacterial susceptibility to the com-
pounds.12 Table I shows that ciproﬂoxacin possessed signiﬁcant
antibacterial activity against the reference bacteria that were
tested, except for A baumannii and K pneumonia, which showed
a zone of inhibition in the intermediate and resistant ranges.
When reference strains were treated with a combination of
ciproﬂoxacin with sildenaﬁl, tadalaﬁl, or vardenaﬁl, the zones of
inhibition of the combination were signiﬁcantly lower than those
of ciproﬂoxacin alone for all tested bacterial strains (Table I).
Table II
Comparison between the MICs (mg/mL) of ciproﬂoxacin alone and ciproﬂoxacin in
the presence of sildenaﬁl, tadalaﬁl, or vardenaﬁl against standard bacterial strains
Standard
bacterial
strains
MIC (mg/mL)*
Ciproﬂoxacin
Ciproﬂoxacin
þ sildenaﬁl
Ciproﬂoxacin
þ tadalaﬁl
Ciproﬂoxacin
þ vardenaﬁl
Escherichia coli 0.02 (0.01) 1300 (100) 1700 (100) 1800 (100)
Staphylococcus
aureus
0.07 (0.05) 1167 (58) 1600 (100) 1833 (58)
Pseudomonas
aeruginosa
0.07 (0.05) 1267 (58) 1700 (100) 1867 (58)
Staphylococcus
epidermidis
0.14 (0.09) 1100 (100) 1500 (100) 1700 (100)
Acinetobacter
baumannii
0.21 (0.07) 1400 (100) 1700 (100) 1767 (58)
Proteus
mirabilis
0.17 (0.07) 1600 (100) 1900 (100) 1933 (58)
Klebsiella
pneumoniae
0.14 (0.09) 933 (57) 1600 (100) 1733 (58)
We investigated whether PDEi could interfere with the antibacterial activity of
ciproﬂoxacin.
Ciproﬂoxacin antibacterial action is inhibited when combined with PDEi
This observation is of signiﬁcance, as ciproﬂoxacin is a commonly used antibiotic
n The MIC values for ciproﬂoxacin alone were signiﬁcantly (P o 0.05) lower
than those of combination of ciproﬂoxacin with sildenaﬁl, tadalaﬁl, or vardenaﬁl for
all tested bacterial strains. Results are presented as mean (SD) of 3 independent
experiments.
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ciproﬂoxacin with sildenaﬁl, tadalaﬁl, or vardenaﬁl were measured
for all tested strains. As shown in Table II, pretreatment of various
reference bacteria cells with a PDEi largely inhibited the antibac-
terial activity of ciproﬂoxacin. This is indicated by signiﬁcantly
higher MIC values (Table II) for the combination of any of the
PDEis (sildenaﬁl, vardenaﬁl, or tadalaﬁl) and ciproﬂoxacin com-
pared with ciproﬂoxacin alone.
To examine the mechanism by which PDEis interfere with the
action of ciproﬂoxacin, the in vitro E coli DNA gyrase cleavage
assay was used. The results showed that ciproﬂoxacin signiﬁcantly
inhibited E coli gyrase activity. However, treatment with PDEi
drugs had no effect on ciproﬂoxacin-induced inhibition of E coli
gyrase activity (Figure 1). Moreover, PDEi drugs alone did not
affect E coli gyrase activity (data not shown).Discussion
Our study showed, for the ﬁrst time, the inhibition of the
antibacterial activity of ciproﬂoxacin when bacteria are pretreated
with any of the PDEis. These results were generated using wideGvrase – + +
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Figure 1. The Escherichia coli DNA gyrase cleavage assay. DNA gyrase was
incubated with supercoiled pBR322 in the presence of 0.1 mg/ML ciproﬂoxacin
(CFX) and/or 1 of the phosphodiesterase inhibitors (100 mM). Bands were separated
using 1% agarose and visualized using ethidium bromide. Phosphodiesterase
inhibitors (100 mM) did not affect antigyrase activity of 0.1 mg/mL CFX.panel of standard bacterial strains and they could be of importance
when ciproﬂoxacin is used on top of PDEis to treat bacterial
infections in older men.
Our results show the efﬁcacy of ciproﬂoxacin on variety of
bacterial strains, including E coli, S aureus, Pseudomonas aerugi-
nosa, S epidermidis, and Proteus mirabilis. In accordance, previous
studies have shown the susceptibility of these bacterial strains to
ciproﬂoxacin.13–14 We and others have previously demonstrated
the crucial role of reactive oxygen species in the antibacterial
action of ciproﬂoxacin on bacterial species, including Pseudomonas
aeruginosa, E coli, and S aureus.13,15–17 On the other hand, common
scavengers of reactive oxygen species, including vitamin C and
vitamin Ε, were shown to attenuate the antibacterial activity of
ciproﬂoxacin.13 Additionally, it was shown that ciproﬂoxacin
induces reactive oxygen species production when it works against
bacterial strains such as E coli, Enterococcus faecalis, and S aureus.16
Furthermore, elevated reactive oxygen species levels were shown
in ciproﬂoxacin-sensitive microorganisms.17 For example,
increased levels of intracellular superoxide were reported in
ciproﬂoxacin-sensitive microorganisms compared with the resist-
ant ones. It was also shown that ascorbic acid or glutathione
application attenuated the antibacterial activity of ciproﬂoxacin
against Escherichia coli, which was dependent on superoxide
anions and hydrogen peroxide scavenging.18
Our present results indicate that combining ciproﬂoxacin with
a PDEi results in inhibition of the antibacterial activity of cipro-
ﬂoxacin against a panel of reference bacterial strains. To our
knowledge, this is the ﬁrst report of such effect or drug-drug
interaction. This could point out that concurrent use of ciproﬂox-
acin with any of the PDEis we tested might oppose the antibacte-
rial activity of this antibiotic. Therefore, PDEi use might need to be
closely monitored in patients who are receiving ciproﬂoxacin.
The mechanism for this interactive effect of ciproﬂoxacin and
PDEis is unknown. Quinolones exert their bactericidal actions
through the inhibition of DNA gyrase, bacterial type II topoiso-
morase.19–20 Yet multiple other effects were related to quinolones,
such as inhibiting the growth of other types of cells21–25 via
interference with cell cycles, reducing cell size,25 inhibiting de
novo synthesis of pyrimidine,25 and interfering with mitochondrial
enzymes that are involved in energy metabolism21 and oxidative
stress.18,26
The PDEis are known to inhibit PDE isoenzymes.1 However,
these agents were shown to possess other effects, such as being
antioxidative or oxidative stress protective,4–5 being immunomo-
dulatory, having anti-inﬂammatory properties,27 and altering
energy metabolism and mitochondrial biogenesis.28 Given the
importance of reactive oxygen species, energy metabolism, and
mitochondrial functions for the antibacterial action of ciproﬂox-
acin,13,15–17 it is possible that these mechanisms play a role in the
observed inhibition of the antibacterial activity of ciproﬂoxacin by
PDEi family members. The results showed an absence of effect for
PDEi drugs on the gyrase inhibitory action of ciproﬂoxacin. Thus, it
is unlikely that PDEi interacts directly with ciproﬂoxacin and
prevents its antigyrase activity. Future studies are needed to
indicate the exact mechanism by which PDEis interfere with the
action of ciproﬂoxacin.
The concentration of PDEis used in this study was generally
lower than that in human plasma as judged from the pharmaco-
kinetic proﬁle of each PDEi.29–31 However, taking into consider-
ation the fraction of each PDEi that is eliminated in the urine—
about 15% for sildenaﬁl29—the used concentration in our study
becomes reasonable. Our study shows the concept of the possible
drug-drug interaction between PDEi family members and cipro-
ﬂoxacin. Future work should focus on a range of relevant
concentrations to further characterize the effect observed in
our study.
M.M. Masadeh et al. / Current Therapeutic Research 77 (2014) 14–17 17Conclusions
The antibacterial action of ciproﬂoxacin is inhibited when
combined with a PDEi, including sildenaﬁl, tadalaﬁl, or vardenaﬁl.
This observation is signiﬁcant because ciproﬂoxacin is a commonly
used antibiotic with huge therapeutic value.Acknowledgment
The authors thank Jordan University of Science and Technology,
Irbid, Jordan, for providing ﬁnancial support (grant No. 117-2013).
M.M. Masadeh designed the study, carried out the antimicrobial
susceptibility and MIC determination experiments, and collected
data. He also participated in data interpretation, ﬁgure creation
and manuscript writing. K.H.Alzoubi participated in literature
review, study design, data collection, ﬁgure creation, data inter-
pretation and drafted the manuscript. O.F.Khabour participated in
study design, carried out the DNA Gyrase experiments, collected
data and participated in data interpretation. He also helped in
drafting the manuscript. S.I.Al-Azzam carried out literature review,
participated in study design, data collection and in manuscript
drafting.Conﬂicts of Interest
The authors have indicated that they have no conﬂicts of
interest regarding the content of this article
References
[1] Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G. Treating erectile
dysfunction and central neurological diseases with oral phosphodiesterase
type 5 inhibitors. Review of the literature. J Sex Med. 2012;9:970–985.
[2] Smith WB 2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, HellstromWJ. PDE5
inhibitors: considerations for preference and long-term adherence. Int J Clin
Pract. 2013;67:768–780.
[3] Patel DN, Li L, Kee CL, Ge X, Low MY, Koh HL. Screening of synthetic PDE-5
inhibitors and their analogues as adulterants: analytical techniques and
challenges. J Pharm Biomed Anal. 2014;87:176–190.
[4] Guzman DC, Olguin HJ, Brizuela NO, Garcia EH, Mejia GB, Jacobo AJ, Abarca LS,
Betancourt ET. Effect of prostaglandin E1 (PGE1) and sildenaﬁl on serotonin
metabolism and some oxidative damage markers in rat prostate gland and
brain. Andrologia. 2011;43:266–272.
[5] Puerta E, Barros-Minones L, Hervias I, Gomez-Rodriguez V, Orejana L, Pizarro
N, de la Torre R, Jordan J, Aguirre N. Long-lasting neuroprotective effect of
sildenaﬁl against 3,4-methylenedioxymethamphetamine- induced 5-
hydroxytryptamine deﬁcits in the rat brain. J Neurosci Res. 2012;90:518–528.
[6] Castro W, Navarro M, Biot C. Medicinal potential of ciproﬂoxacin and its
derivatives. Future Med Chem. 2013;5:81–96.
[7] Nam YS, Cho SY, Yang HY, Park KS, Jang JH, Kim YT, Jeong JW, Suh JT, Lee HJ.
Investigation of mutation distribution in DNA gyrase and topoisomerase IV
genes in ciproﬂoxacin-non-susceptible Enterobacteriaceae isolated from blood
cultures in a tertiary care university hospital in South Korea, 2005-2010. Int
J Antimicrob Agents. 2013;41:126–129.
[8] Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated quinolone
resistance: a multifaceted threat. Clin Microbiol Rev. 2009;22:664–689.[9] Qin N, Baehr W. Expression of mouse rod photoreceptor cGMP phosphodies-
terase gamma subunit in bacteria. FEBS Lett. 1993;321:6–10.
[10] Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB,
Abadi AH, et al. Sulindac selectively inhibits colon tumor cell growth by
activating the cGMP/PKG pathway to suppress Wnt/beta-catenin signaling.
Mol Cancer Ther. 2013;12:1848–1859.
[11] Hedaya MA, El-Aﬁfy DR, El-Maghraby GM. The effect of ciproﬂoxacin and
clarithromycin on sildenaﬁl oral bioavailability in human volunteers. Biopharm
Drug Dispos. 2006;27:103–110.
[12] CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 22end
Informational supplement, Villanova, NCCLS, M100-S22. 2012.
[13] Masadeh MM, Mhaidat NM, Alzoubi KH, Al-Azzam SI, Shaweesh AI.
Ciproﬂoxacin-induced antibacterial activity is reversed by vitamin E and
vitamin C. Curr Microbiol. 2012;64:457–462.
[14] Campoli-Richards DM, Monk JP, Price A, Benﬁeld P, Todd PA, Ward A.
Ciproﬂoxacin. A review of its antibacterial activity, pharmacokinetic properties
and therapeutic use. Drugs. 1988;35:373–447.
[15] Umezawa N, Arakane K, Ryu A, Mashiko S, Hirobe M, Nagano T. Participation
of reactive oxygen species in phototoxicity induced by quinolone antibacterial
agents. Arch Biochem Biophys. 1997;342:275–281.
[16] Albesa I, Becerra MC, Battan PC, Paez PL. Oxidative stress involved in the
antibacterial action of different antibiotics. Biochem Biophys Res Commun.
2004;317:605–609.
[17] Becerra MC, Albesa I. Oxidative stress induced by ciproﬂoxacin in Staph-
ylococcus aureus. Biochem Biophys Res Commun. 2002;297:1003–1007.
[18] Goswami M, Mangoli SH, Jawali N. Involvement of reactive oxygen species in
the action of ciproﬂoxacin against Escherichia coli. Antimicrob Agents Chemo-
ther. 2006;50:949–954.
[19] Gootz TD, Barrett JF, Sutcliffe JA. Inhibitory effects of quinolone antibacterial
agents on eucaryotic topoisomerases and related test systems. Antimicrob
Agents Chemother. 1990;34:8–12.
[20] Gellert M. DNA topoisomerases. Annu Rev Biochem. 1981;50:879–910.
[21] Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC. 4-Quinolones cause
a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell
Biochem. 1993;51:165–174.
[22] Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage
of mitochondrial DNA in ciproﬂoxacin-treated mammalian cells. Mol Pharma-
col. 1996;50:1178–1188.
[23] Nordmann P, Pechinot A, Kazmierczak A. Cytotoxicity and uptake of peﬂox-
acin, ciproﬂoxacin, and oﬂoxacin in primary cultures of rat hepatocytes. J
Antimicrob Chemother. 1989;24:355–363.
[24] Oomori Y, Yasue T, Aoyama H, Hirai K, Suzue S, Yokota T. Effects of ﬂeroxacin
on HeLa cell functions and topoisomerase II. J Antimicrob Chemother. 1988;22
Suppl D:91–97.
[25] Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF. Effects of
ciproﬂoxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell
growth. Antimicrob Agents Chemother. 1987;31:774–779.
[26] Gurbay A, Hincal F. Ciproﬂoxacin-induced glutathione redox status alterations
in rat tissues. Drug Chem Toxicol. 2004;27:233–242.
[27] Lubamba B, Huaux F, Lebacq J, Marbaix E, Dhooghe B, Panin N, Wallemacq P,
Leal T. Immunomodulatory activity of vardenaﬁl on induced lung inﬂamma-
tion in cystic ﬁbrosis mice. J Cyst Fibros. 2012;11:266–273.
[28] De Toni L, Strapazzon G, Gianesello L, Caretta N, Pilon C, Bruttocao A, Foresta C.
Effects of type 5-phosphodiesterase inhibition on energy metabolism and
mitochondrial biogenesis in human adipose tissue ex vivo. J Endocrinol Invest.
2011;34:738–741.
[29] Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharma-
cokinetics and metabolism of single-dose oral and intravenous sildenaﬁl. Br J
Clin Pharmacol. 2002;53 Suppl 1:13S–20S.
[30] Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE,
Mitchell MI. Tadalaﬁl pharmacokinetics in healthy subjects. Br J Clin Pharma-
col. 2006;61:280–288.
[31] Bischoff E. Vardenaﬁl preclinical trial data: potency, pharmacodynamics,
pharmacokinetics, and adverse events. Int J Impot Res. 2004;16(Suppl 1):
S34–S37.
